TY - JOUR
T1 - Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival
AU - Raffel, Jennifer
AU - Bhattacharyya, Achyut K.
AU - Gallegos, Alfred
AU - Cui, Haiyan
AU - Einspahr, Janine G.
AU - Alberts, David S.
AU - Powis, Garth
N1 - Funding Information:
Supported by National Institutes of Health grants CA90821, CA95060, and CA77204.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Thioredoxin-1 is a redox protein that, when overexpressed, causes increased cancer-cell growth and inhibited apoptosis. Thioredoxin-1 expression has been reported to be increased in several human primary tumors, but its relationship to tumor progression and patient survival has not been established. We studied the expression of thioredoxin-1 as measured with immunohistochemical staining in paraffin-embedded human normal colonic mucosa, adenomatous polyps, and primary and metastatic colorectal cancer. Thioredoxin-1 expression was not increased in 12 colorectal adenomatous polyps, compared with 8 samples of normal colonic mucosa, but was significantly increased in 12 primary colorectal cancers (P < .01). Thioredoxin-1 expression was not significantly different in primary lymph-node metastases and the primary colorectal cancer. Using colorectal cancer samples from 37 subjects for whom survival data was available, we found that thioredoxin-1 expression increased with Dukes stage, although the association was not statistically significant (P = .077). We noted a significant association between thioredoxin-1 expression and patient survival (P = .004); higher score was associated with decreased survival. When adjusted for Dukes stage, thioredoxin-1 expression showed a statistically significant association with survival (P = .012). The work shows that increased thioredoxin-1 expression is a relatively late event in colorectal carcinogenesis and provides evidence in a small group of subjects with colorectal cancer of Dukes stages A through D that thioredoxin-1 expression may be an independent marker of patient prognosis.
AB - Thioredoxin-1 is a redox protein that, when overexpressed, causes increased cancer-cell growth and inhibited apoptosis. Thioredoxin-1 expression has been reported to be increased in several human primary tumors, but its relationship to tumor progression and patient survival has not been established. We studied the expression of thioredoxin-1 as measured with immunohistochemical staining in paraffin-embedded human normal colonic mucosa, adenomatous polyps, and primary and metastatic colorectal cancer. Thioredoxin-1 expression was not increased in 12 colorectal adenomatous polyps, compared with 8 samples of normal colonic mucosa, but was significantly increased in 12 primary colorectal cancers (P < .01). Thioredoxin-1 expression was not significantly different in primary lymph-node metastases and the primary colorectal cancer. Using colorectal cancer samples from 37 subjects for whom survival data was available, we found that thioredoxin-1 expression increased with Dukes stage, although the association was not statistically significant (P = .077). We noted a significant association between thioredoxin-1 expression and patient survival (P = .004); higher score was associated with decreased survival. When adjusted for Dukes stage, thioredoxin-1 expression showed a statistically significant association with survival (P = .012). The work shows that increased thioredoxin-1 expression is a relatively late event in colorectal carcinogenesis and provides evidence in a small group of subjects with colorectal cancer of Dukes stages A through D that thioredoxin-1 expression may be an independent marker of patient prognosis.
UR - http://www.scopus.com/inward/record.url?scp=0042991494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042991494&partnerID=8YFLogxK
U2 - 10.1016/S0022-2143(03)00068-4
DO - 10.1016/S0022-2143(03)00068-4
M3 - Article
C2 - 12878985
AN - SCOPUS:0042991494
SN - 0022-2143
VL - 142
SP - 46
EP - 51
JO - Journal of Laboratory and Clinical Medicine
JF - Journal of Laboratory and Clinical Medicine
IS - 1
ER -